Clinical Trials Logo

Stage IIIA Melanoma clinical trials

View clinical trials related to Stage IIIA Melanoma.

Filter by:

NCT ID: NCT01321437 Completed - Melanoma Clinical Trials

Study of the Anti-Angiogenesis Agent Axitinib in Patients With Stage III Malignant Melanoma

Start date: December 2011
Phase: Phase 2
Study type: Interventional

The purpose of this research study is to determine the efficacy of Axitinib in treating individuals with Stage III melanoma.

NCT ID: NCT00470470 Completed - Recurrent Melanoma Clinical Trials

Imatinib Mesylate in Treating Patients With Stage III or Stage IV Melanoma That Cannot Be Removed by Surgery

Start date: April 2007
Phase: Phase 2
Study type: Interventional

This phase II trial is studying how well imatinib mesylate works in treating patients with stage III or stage IV melanoma that cannot be removed by surgery. Imatinib mesylate may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth.

NCT ID: NCT00436605 Completed - Recurrent Melanoma Clinical Trials

Dasatinib in Treating Patients With Stage III Melanoma That Cannot Be Removed By Surgery or Stage IV Melanoma

Start date: December 2006
Phase: Phase 2
Study type: Interventional

This phase II trial is studying how well dasatinib works in treating patients with stage III melanoma that cannot be removed by surgery or stage IV melanoma. Dasatinib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth.

NCT ID: NCT00089063 Completed - Stage IV Melanoma Clinical Trials

Vaccine Therapy With or Without Sargramostim in Treating Patients Who Have Undergone Surgery for Melanoma

Start date: June 2004
Phase: Phase 2
Study type: Interventional

This randomized phase II trial is studying vaccine therapy and sargramostim to see how well they work compared to vaccine therapy alone in treating patients who have undergone surgery for stage IIB, stage IIC, stage III, or stage IV melanoma. Vaccines made from peptides may make the body build an immune response to kill tumor cells. Colony-stimulating factors such as sargramostim increase the number of immune cells found in bone marrow or peripheral blood. Combining vaccine therapy with sargramostim may make a stronger immune response.

NCT ID: NCT00085189 Completed - Recurrent Melanoma Clinical Trials

Vaccine Therapy in Treating Patients With Stage IIC-IV Melanoma

Start date: May 2004
Phase: Phase 2
Study type: Interventional

This pilot phase II trial studies how well giving vaccine therapy works in treating patients with stage IIC-IV melanoma. Vaccines made from melanoma peptides or antigens may help the body build an effective immune response to kill tumor cells

NCT ID: NCT00003895 Completed - Recurrent Melanoma Clinical Trials

Vaccine Therapy in Treating HLA-A2 Positive Patients With Melanoma

Start date: April 1999
Phase: Phase 2
Study type: Interventional

This randomized pilot phase II trial studies how well vaccine therapy works in treating human leukocyte antigen class 1 histocompatibility, A-2 (HLA-A2) positive patients with melanoma. Vaccines made from peptides may help the body build an effective immune response to kill tumor cells.